23-Jan-2026
Quest Diagnostics Named to Fortune's World's Most Admired Companies List for 12th Consecutive Year
PRNewswire (Wed, 21-Jan 2:36 PM ET)
Sonora Quest and Laboratory Sciences of Arizona Announce Jennifer Erickson as CEO-Elect
PRNewswire (Thu, 15-Jan 9:01 AM ET)
Quanterix Appoints Everett Cunningham as President and CEO Effective January 19, 2026
Business Wire (Thu, 8-Jan 4:30 PM ET)
PRNewswire (Thu, 8-Jan 10:00 AM ET)
PRNewswire (Tue, 6-Jan 10:02 AM ET)
Corewell Health and Quest Diagnostics Complete Laboratory Joint Venture Transaction in Michigan
PRNewswire (Mon, 5-Jan 8:58 AM ET)
Quest Diagnostics to Speak at the 44th Annual J.P. Morgan Healthcare Conference
PRNewswire (Fri, 19-Dec 3:21 PM ET)
Business Wire (Mon, 1-Dec 8:30 AM ET)
Engine Capital Issues Open Letter to the Trustees Controlling UniFirst Corporation
Business Wire (Tue, 25-Nov 9:15 AM ET)
Quest Diagnostics Declares Quarterly Cash Dividend
PRNewswire (Tue, 11-Nov 4:30 PM ET)
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the US. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.
Quest Diagnostics trades on the NYSE stock market under the symbol DGX.
As of January 23, 2026, DGX stock price declined to $181.02 with 786,618 million shares trading.
DGX has a beta of 0.16, meaning it tends to be less sensitive to market movements. DGX has a correlation of 0.02 to the broad based SPY ETF.
DGX has a market cap of $20.14 billion. This is considered a Large Cap stock.
Last quarter Quest Diagnostics reported $3 billion in Revenue and $2.60 earnings per share. This beat revenue expectation by $87 million and exceeded earnings estimates by $.09.
In the last 3 years, DGX traded as high as $197.55 and as low as $119.59.
The top ETF exchange traded funds that DGX belongs to (by Net Assets): VTI, VOO, VO, IVV, SPY.
DGX has outperformed the market in the last year with a price return of +21.3% while the SPY ETF gained +14.2%. However, in the short term, DGX had mixed performance relative to the market. It has underperformed in the last 3 months, returning -0.8% vs +2.9% return in SPY. But in the last 2 weeks, DGX shares have fared better than the market returning +4.2% compared to SPY -0.7%.
DGX support price is $179.13 and resistance is $185.20 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that DGX shares will trade within this expected range on the day.